Working… Menu

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma (INITIATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03048474
Recruitment Status : Completed
First Posted : February 9, 2017
Last Update Posted : January 20, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
The Netherlands Cancer Institute